Revtorpyk (gedatolisib)
Celcuity (CELC)
ApprovedJul 14, 2026
Marketer take
Labeled for HR+/HER2- breast cancer without a PIK3CA mutation, a different slice of post-endocrine disease than PI3K-pathway drugs aimed at mutated tumors, so biomarker results will steer the oncologist conversation.
- Sponsor company
- Celcuity (CELC)
- Indication
- In combination with fulvestran, to treat hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting
- Therapeutic area
- Oncology
- Event
- FDA approval
- Date
- Jul 14, 2026
- Status
- Approved
- Source
- FDA page
- Last verified
- Nov 15, 2026
Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?